Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk

Fig. 2

Design of the CARMELINA® trial. *Additional glucose-lowering therapy may be given on top of study medication if HbA1c > 7.5%; investigators are encouraged to treat all other CV risk factors in accordance with local or regional standards of care. †Participants who stop study drug early are observed until study end (not just until 30 days after the end of treatment with study drug). CV cardiovascular, HbA1c glycated hemoglobin A1c

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840